The N-terminal hydrophilic ectodomain of the G L envelope glycoprotein of equine arteritis virus (EAV) contains neutralization determinants of the virus. We developed a panel of 17 neutralizing murine monoclonal antibodies (MAbs) to further characterize the neutralization determinants of EAV. Included were 6 MAbs previously raised against a laboratory strain (EAVUCD) of the original Bucyrus strain of EAV, as well as 11 additional MAbs that were raised against a neutralizationresistant variant [escape mutant (EM)] virus (EM6D10) that was derived from EAVUCD. All MAbs raised against EAVUCD and 4 of the MAbs raised against EM6D10 (2B3, 5F8, 8D4, and 10B4) reacted with the corresponding G L envelope glycoprotein in a Western immunoblotting assay, whereas the remaining 7 MAbs raised against EM6D10 did not react with any viral protein in the immunoblotting assay but competitively inhibited the binding of MAbs 2B3, 5F8, 8D4, and 10B4, indicating that they also recognize epitopes on the G L protein. 
INTRODUCTION
on Taxonomy of Viruses (ICTV) placed these four viruses in an independent family Arteriviridae containing a single Equine arteritis virus (EAV) is distributed throughout genus Arterivirus (Murphy, 1997) . The committee also the world and causes periodic outbreaks of equine viral created an order Nidovirales that includes the families arteritis (EVA) in horses (Akashi et al., 1975; Moraillon Arteriviridae and Coronaviridae. and Moraillon, 1978; McCollum and Bryans, 1973; Hun- The EAV genome consist of 12,704 nucleotides and tington et Camm and Thursby-Pelham, 1993;  includes at least eight open reading frames (ORFs: 1a, Nosetto et al., 1984) . EAV infection can cause pneumonia 1b, 2, 3, 4, 5, 6, and 7; den Boon et al., 1991) . The ORFs in very young foals, abortion in pregnant mares, and per1a and 1b are approximately 9.5 kb in length, are located sistent infection of stallions (Carman et al., 1988; at the 5 end of the genome, and encode the viral repliet al. Doll et al., 1957a,b; case. The ORFs 2 to 7 are located within 2.9 kb at the 1981). EAV is an enveloped, positive-stranded RNA virus 3 end of the genome and during replication a nested (Horzinek, 1981) , and it recently has been demonstrated set of six 3-coterminal viral subgenomic mRNAs are that EAV resembles lactate dehydrogenase-elevating viproduced (den Boon et al., 1991 and de Vries et al., 1990) . rus, porcine reproductive and respiratory syndrome virus, The ORFs 2, 5, and 6 encode known viral membrane and simian hemorrhagic fever virus in its genome organiproteins; ORF7 encodes the 14-kDa nucleocapsid protein zation, replication strategy, and tropism for macrophages de Vries et al., 1992) . The ORFs 2 and 5, respectively, (den Boon et al., 1991; Meulenberg et al., 1994) . Because encode 25-(G S ) and 30-kDa (G L ) envelope glycoproteins, of their similarities, in 1996 the International Committee whereas ORF6 encodes a 17-kDa unglycosylated envelope protein (M). Genomic variation among field strains of EAV has been (Murphy et al., 1988 and sequence analysis of ble for differences in neutralization phenotype of the various viruses. ORFs 6 and 7 Sugita et al., 1994) . We recently have reported the genetic variation and phylogenetic analysis of ORF2 and ORF5 of a large number MATERIALS AND METHODS of field isolates and laboratory strains of EAV, and the Cells and viruses modified-live vaccine virus (Balasuriya et al., 1995b; Hedges et al., 1996) . Comparison of the deduced amino Rabbit kidney 13 (RK-13; ATCC CCL 37) cells were acid sequences of the G L protein of these viruses identimaintained in Dulbecco's modified Eagle's medium fied a putative signal sequence [S (aa 1-18)], three dis-(DMEM) supplemented with 10% heat-inactivated calf setinct variable regions [V 1 (aa 61-121), V 2 (141-178), V 3 rum (CS; Hyclone Laboratories, Inc., Logan, UT), 100 IU (202-222)], and four conserved regions [C 1 (aa 19-60), of Penicillin, and 100 mg of Streptomycin per milliliter. C 2 (122-140), C 3 (179-201), and C 4 (223-255)].
Murine myeloma P3X63Ag8.653 cells were obtained from Although there apparently is only one serotype of EAV, the American Type Culture Collection (Bethesda, MD; there appears to be considerable antigenic variation Kearney et al., 1979) and cultured in RPMI 1640 (Bioamong field strains based on their neutralization by Whittaker, Walkersville, MD) supplemented with 10% CS, monoclonal and polyclonal antisera, and the requirement 5% hybridoma growth factor from murine P388D1 cells for complement for effective neutralization of some (Bazin and Lemieux, 1987) , 0.1% 10 mM nonessential strains (McCollum and Swerczek, 1978; amino acids, and 1% 100 mM sodium pyruvate (Sigma, 1986; Murphy et al., 1988; Fukunaga et al., 1993  St. Louis, MO). Fukunaga and McCollum, 1977; Glaser et al., 1995, The phenotypic variation of 22 laboratory strains [inKondo et al., 1994; Westcott et al., 1995) . In addition, cluding EAVUCD, EAV X2.4, EAVCVDLS, EAVATCC geographically and temporally distinct EAV isolates differ (ATCC VR-796) and 18 EM viruses; see below], the modiin the severity of the clinical disease they induce and in fied live virus vaccine (ARVAC, Fort Dodge Laboratories, their abortigenic potential (McCollum and Swerczek, IA) , and 19 field strains of EAV was determined. The 1978; Timoney and McCollum, 1993) . The G L protein enfield isolates were collected over a 40-year period from coded by ORF5 expresses the known neutralization dethroughout the United States (VBS53, PA76, KY63, KY77, terminants of EAV (Chirnside et al., 1995; Glaser et al., KY84, KY93, AZ87, NE88, NE89, MT89, MI93, IL93AB, and 1995; Balasuriya et al., 1993 Balasuriya et al., , 1995a Deregt et al., 1994, IL93TB) , western Canada (CAN86), and Europe (SWZ64, Westcott et al., 1995) . We previously have shown that AUT68, PLD76, and ITA92). Passage histories of these amino acids 99 through 104 of the G L envelope glycoproviruses have been previously reported (Balasuriya et al. , tein are critical for virus neutralization (Balasuriya et al., 1995b) . The isolation and genotypic characterization of 1995a). In addition, we have demonstrated that the majortwo strains of EAV isolated from the semen of two persisity of amino acid substitutions in the G L protein of field tently infected stallions in California (CA95G and CA95I) isolates of EAV are localized to the V 1 (aa 61-121) variwill be published elsewhere (Balasuriya et al., 1997b) . able region (Balasuriya et al., 1995b) . We predict, thereAll EM viruses ultimately were derived from our protofore, that these amino acid changes in the V 1 region of type strain of EAV (EAVUCD), which originally was dethe G L protein would alter the neutralization determinants rived from the Bucyrus strain of EAV that was obtained of EAV, perhaps leading to antigenic variation among from the National Veterinary Services Laboratory, Ames, EAV strains.
IA (EAV-NVSL; this virus was generously provided by The objectives of this study were to further characterDr. A. Castro, California Veterinary Diagnostic Laboratory ize the neutralization determinants of EAV and to characSystem, Davis, CA). The passage history of the EAVUCD terize variation in the neutralization phenotype of a large prototype has been previously reported (Balasuriya et al. , panel of field isolates and laboratory strains of EAV. Char1995a,b) . acterization of the neutralization determinants of EAV is prerequisite to the logical development of improved vacPolyclonal anti-sera cines and diagnostic methodologies for EAV. To achieve these objectives, large panels of neutralizing MAbs and Anti-EAV equine sera from a horse inoculated with the Bucyrus strain of EAV (EqKy; Balasuriya et al., 1993) and neutralization-resistant variant [escape mutant (EM)] viruses were developed. The genotypic and phenotypic three persistently infected stallions from California (G, I, and J) were used to phenotypically characterize the varicharacterization of these EM viruses identified a number of conformational and nonconformational neutralization ous strains of EAV. Anti-EAV hyperimmune rabbit serum (No. 5595) was produced by immunizing New Zealand determinants of EAV. The MAbs were then used for phenotypic characterization of field isolates of EAV, and comwhite rabbits with the EAVUCD laboratory strain. Briefly, the supernatant from EAVUCD-infected RK-13 cells was parison of data obtained from these studies with that from the EM viruses showed that antigenic variation in ultracentrifuged at 120,000 g for 4 hr at 4Њ. The virus pellet was resuspended in NET buffer (150 mM NaCl, 5 the V 1 region of the G L protein principally was responsi-mM EDTA, and 50 mM Tris, pH 7.5) and the rabbits were et al., 1993, 1995a) . EAVUCD and EM6D10 were used as antigens for screening and characterization of the MAbs. initially immunized by subcutaneous (S/C) injection of 1:2 emulsion of virus in Freund's complete adjuvant. Rabbits
Competitive ELISA (cELISA) were subsequently boosted three times (2 weeks apart) by S/C injection of the same antigen in Freund's incomThe MAbs raised against EM6D10 were further charplete adjuvant. Serum from an uninfected horse (EqDG) acterized by cELISA to demonstrate that neutralizing epiand preinoculation rabbit serum were used as the negatopes recognized by MAbs in the panel are located in tive controls. All sera were heat inactivated (56Њ for 30 the G L major envelope glycoprotein of EAV, as previously min) and stored at 020Њ.
described (Balasuriya et al., 1993) . ELISA plates were coated with cesium chloride (CsCl) gradient-purified Generation and characterization of monoclonal EM6D10 at a concentration of 30 mg/ml in coating buffer antibodies (MAbs) (150 mM sodium chloride, 70 mM sodium phosphate buffer, 1% lactose, pH 8.0; Balasuriya et al., 1993) . Log The generation and characterization of six neutralizing dilutions (50 to 50,000 ng/ml) of unbiotinylated inhibitory MAbs to the prototype strain of EAVUCD (5G11, 6D10, MAb and biotinylated test MAb (2,000 ng/ml) were re-7E5, 9F2, 10F11, and 10H4) used in this study were deacted to determine the ability of the unbiotinylated inhibiscribed previously (Balasuriya et al., 1993 (Balasuriya et al., , 1995a Balasuriya et al., zyme-substrate system. Inhibition of binding of the biotin1995a). MAbs to EM6D10 were produced according to ylated MAb by each unbiotinylated MAb was then calcustandard protocols similar to those previously described lated and expressed as a percentage. Inhibition that was (Heidner et al., 1988; Balasuriya et al., 1993) . Briefly, mice §50% at 50,000 ng/ml of inhibitory IgG was regarded as were initially immunized by intravenous (I/V) injection of positive. gradient purified EM6D10 (Balasuriya et al., 1995a) , and subsequently boosted three times (10-14 days apart) by Phenotypic characterization of laboratory strains and intraperitoneal (I/P) injection of the same antigen (1:2 field isolates of EAV emulsion in Freund's complete or incomplete adjuvant). The mice were I/V administered with virus 3 days prior Antibody titers of MAbs (ascitic fluid) and polyclonal to fusion. Fusion of splenic lymphocytes with cells from antiserum were determined by microneutralization assay the P3X63Ag8.653 myeloma cell line (Kearney et al., using EM6D10 as the challenge virus, in the absence 1979) was done in the presence of polyethylene glycol of complement (Balasuriya et al., 1993) . Heat-inactivated in RPMI medium. Hybridomas secreting EAV-specific sera and ascitic fluid were diluted twofold in MEM. The neutralizing MAbs were identified by microneutralization initial dilution of serum was 1:16 and 1:100 for ascitic assay and cloned three times by limiting dilution in 96-fluid. Diluted sera or ascitic fluid was mixed with approxiwell plates (Lietzke and Unsicker, 1985) . mately 500 TCID 50 of EM6D10 for 30 min at 37Њ. RK-13 Ascitic fluid was produced by I/P administration of cells then were added and cultures were incubated at 37Њ each hybridoma into BALB/c mice. Mice were primed for 60-72 hr until cytopathic effect had fully developed by two I/P injections of 0.5 ml of pristane (2, 6, 10, 14-in control wells. Antibody titers were recorded as the tetramethyl pentadecane; Sigma, St. Louis, MO) at a 5-reciprocal of the highest final dilution that provided at week interval prior to inoculation of hybridoma cells. least 50% protection of the monolayer. Immunoglobulin isotyping was done by ELISA using a commercial kit (Sigma, St. Louis, MO). Purified immunoGeneration of neutralization-resistant variant viruses globulin G (IgG) from each MAb and the polyclonal to MAbs equine antisera was prepared with ABX 40-mm ion ex-
The production and characterization of seven EM vichange resin (J. T. Baker Inc., Phillipsburg, NJ). Each ruses to the panel of six MAbs raised to EAVUCD has MAb was biotinylated according to a method previously been previously described (EM5G11, EM6D10, EM7E5, described (Liddell and Cryer, 1991; Goding, 1986 Alameda, CA) according to the manufacturer's instructions. Nucleotide sequences were translated into the respective amino acid sequences with a Power Macintosh PCR amplification and sequencing of ORF5 8100/100AV computer using HIBIO MacDNASIS Pro VerTotal RNA was extracted from virus-infected RK-13 cells sion 3.5 software (Hitachi Software Engineering Co., Ltd., using guanidinium thiocyanate and phenol (RNAzol B; TelSan Bruno, CA). Test, Inc., Friendswood, TX) according to the manufacturers protocol and as previously described (Balasuriya et al., 1995a,b) . The published sequence of a laboratory strain of RESULTS the original Bucyrus virus (EAVUtr; den Boon et al., 1991, Generation and characterization of monoclonal GenBank Accession No. X53459) was used to design synantibodies thetic oligodeoxynucleotide primers (National Biosciences Inc., St. Paul, MN) for amplification and sequencing of
The production and characterization of the six neu-ORF5 and flanking portions of ORF4 and ORF6 from each tralizing MAbs to EAVUCD has been previously de-EM virus, as previously described (Balasuriya et al., scribed (Balasuriya et al., 1993 (Balasuriya et al., , 1995a . Eleven additional 1995a,b); positive primers: 11, 023-11,042, 11,255-11,276, hybridomas which produced EM6D10-specific antibod-11, 540-11,561; negative primers: 11,978-11,998, 11,940- ies were identified by microneutralization and Western 11, 961, 11, 695, 11, 445, 11, 239) .
immunoblotting assays using EM6D10 as antigen. The The negative primer 11,978-11,998 was used to reverse immunoglobulin isotype and neutralization titer of each transcribe the positive-sense viral RNA to cDNA. PCR amMAb is listed in Table 1 . Four of the neutralizing MAbs plification was then carried out with the 11,023-11,042 (2B3, 5F8, 8D4, and 10B4) strongly reacted with the G L and 11,978-11,998 primers. The GeneAmp RNA PCR kit protein in a Western immunoblotting assay ( Fig. 1 , repre-(Perkin-Elmer Corp., Foster City, CA) was used for resentative examples are in lanes 5 and 7), whereas seven verse transcription of the viral RNA to cDNA and for subseof the neutralizing MAbs did not react with any viral proquent amplification of the cDNA (Balasuriya et al., 1995a) . tein in the immunoblotting assay ( Fig. 1 , representative Both positive and negative strands of cDNA from each examples are in lanes 6 and 9) and their protein specificamplicon were sequenced with at least three primers per ity was defined by two way cELISA with biotinylated and strand using the PRISM Ready Reaction DyeDeoxy Termiunbiotinylated MAbs. These seven MAbs strongly inhibnator (Applied Biosystems, Alameda, CA) cycle sequencited ( §50% inhibition) the binding of MAbs 2B3, 5F8, 8D4, ing kit. Approximately 150-200 ng cDNA and 10 pmol and 10B4, indicating that they recognize conformationally primer were used in each reaction. Fluorescently labeled dideoxynucleotides were directly incorporated into extendependent epitopes on the G L protein (data not shown).
FIG. 1.
Representative examples of immunoblotting of the prototype (EAVUCD) and neutralization-resistant (EM6D10) viruses with MAbs and polyclonal equine antisera. The antigen present in each lane is indicated immediately beneath the lane number, and the specific blotting antibody (IgG or tissue culture fluid) is identified below the lane. MAb 7B9 specific for the nucleocapsid protein of EAV and normal equine serum are used as controls (Balasuriya, 1997a) . The M r of significant EAV proteins are indicated on the right, and the specific structural proteins identified by the MAbs and polyclonal equine serum are indicated on the left.
Neutralization phenotype of neutralization-resistant
tralized by MAbs 3F4, 5E8, 7D4, and 10B4, to titers that varied from 400 to 12,800. These data, together with variant viruses those of the competitive binding studies, suggest that A panel of DEM viruses was derived from EM6D10 the MAbs recognize multiple linear and conformationally using the MAb panel. The neutralization phenotype of dependent neutralization determinants on the G L enveeach virus was characterized by microneutralization lope glycoprotein of EAV. assay using the MAb panel and polyclonal anti-EAV Anti-EAV serum derived from horses that were naturally equine and rabbit sera. A fourfold or greater difference infected with EAV also neutralized the EM viruses to variin neutralization titer between viruses was regarded as able titers (16 to 512; Table 2 ). As compared to the other a significant change in neutralization phenotype (Table  EM viruses, however, the DEMs 3F4. 8 and 10B4. 3 were 2). All DEMs were not neutralized by the MAb used for neutralized to low titers by equine anti-EAV sera (16 to their selection. With the notable exception of MAb 1H7, 64). Equine anti-EAV serum (EqKy) derived from a horse DEMs 3F4. 8, and 10B4. 3 were not consistently neutralexperimentally inoculated with the original Bucyrus virus ized by any of the MAbs in the panel. With the exception neutralized all the viruses to titers of 128 to 512. Polyclonal of DEMs 1H7. 13, 1H9. 7, 5E8. 22, 6A2. 12, 7D4. 30, and anti-EAV rabbit serum neutralized most EM viruses to titers 10B4. 9, which were neutralized by MAb 10H4 to titers that ranged from 64 to 256 (Table 2) , but the rabbit antiseranging from 1,600 to 12,800, the DEMs were not neutralrum failed to neutralize either DEM 3F4. 8 or 10B4. 3. ized by any of the MAbs raised against EAVUCD (MAbs 5G11, 6D10, 7E5, 9F2, 10F11, and 10H4). All the MAbs Sequence alterations in ORF5 and amino acid raised against EM6D10 neutralized DEM 1H7. 13 except substitutions in the G L protein that confer resistance MAb 1H9, and the DEM 1H9. 7 was neutralized by all of EM viruses to neutralization MAbs raised against EM6D10 except MAbs 6A2 and 7D4. The DEMs 2B3. 20, 2B3. 25, and 8D4. 18 had a ORF5 from each DEM virus was sequenced in its entirety and compared to that of EAVUCD. EAVUCD is similar neutralization phenotype; however, 8D4. 18 was neutralized to a lower titer (800) by MAb 6A2 as comthe parent virus of EM6D10 (Balasuriya et al., 1995a) and all the DEMs used in this study were derived from pared to DEMs to 2B3. 20 and 2B3. 25 (12,800) . DEMs 5F8. 6 and 10B4. 9 had a similar neutralization phenotype; EM 6D10. The nucleotide and amino acid substitutions in each DEM virus are indicated in Table 4 and both however, DEM 5F8. 6 escaped neutralization by MAb 10H4, whereas DEM 10B4. 9 was neutralized by the the nucleotide and the amino acid sequences of DEMs are numbered according to the published sequence of same MAb to a significant titer (1600). DEMs 6A2. 12 and 7D4. 30 had a similar neutralization phenotype, but EAVUtr (den Boon et al., 1991) for consistency. All the DEMs consistently maintained the nucleotide change neutralization titers differed by at least fourfold with MAbs 1H7, 3F4, 5F8, and 7C5. DEM 5E8. 22 was neutralat position 11,423 of ORF5 that is present in EM6D10. The nucleotide at position 11,423 was changed to G ized by all but 2 MAbs (1H9 and 8D4) to variable titers ranging from 800 to 12,800. DEM 7C5. 17 was only neu-(T r G as compared to EAVUCD or C r G as compared to the EM 6D10) in DEM 2B3. 25. The nucleotide at position 11,424 of this virus also was changed from A to T. Both changes produce a codon change (TAC r GTC) resulting in a tyrosine to valine substitution (histidine to valine as compared to EM 6D10) at position 99 of DEM 2B3.25. Another DEM (2B3. 20) to the same antibody (MAb 2B3) had only the latter nucleotide change (A r T), which resulted in a tyrosine to leucine (histidine to leucine as compared to EM 6D10) at position 99. Similarly, the nucleotide change at 11,424 of three other DEMs (5F8. 6, 8D4. 18, and 10B4. 9) resulted in proline and leucine substitutions at position 99 (Table 4 and Fig. 2 ). All such changes at position 99 were from uncharged polar (basic as compared to EM 6D10) to nonpolar amino acids (leucine, valine, or proline) and change the neutralization phenotype of DEM 2B3. 30, 2B3, 25, 5F8. 6, 8D4. 18, and 10B4. 9. These findings strongly suggest that MAbs 2B3, 5F8, 8D4, and 10B4 recognized the same or overlapping epitopes at position 99. The fact that these four MAbs bind the G L protein of EM6D10 in a Western immunoblotting assay further suggests that they recognize a linear epitope that centers on amino acid 99 of the G L protein.
DEMs 1H9. 7, 6A2. 12, and 7D4. 30 had the same nucleotide change at position 11,334 and hence the same amino acid substitution (leucine to proline) at position 69. Except for DEM 5F8.6 and 10B4.9, all the other DEMs were not neutralized by MAb 1H9. This suggests that the epitope recognized by 1H9 is conformational and formed by amino acid 69 and the four amino acids from 99 to 102. MAb 6A2 did not neutralize DEM 7C5. 17, which had a leucine to glutamine substitution at position 102, suggesting that the epitope recognized by MAb 6A2 is conformational and formed by amino acids 69 and 102. MAb 7D4 neutralized all the DEMs that had amino acid substitutions at positions 99 and 102, indicating that it recognizes a distinct but overlapping conformational epitope. In contrast to MAb 7D4, the MAbs 1H9 and 6A2 do not neutralize DEM 6D10/10H4, which has a phenylalanine to serine substitution at position 103. In addition DEMs 1H9. 7, 6A2. 12, and 7D4. 30 were also neutralized by MAb 10H4, which recognizes a linear epitope at amino acids 102 and 103 (Balasuriya et al., 1995a; Fig. 2) . Thus, MAbs 1H9, 6A2, and 7D4 most likely identify the same or overlapping conformational epitope(s) formed by amino acids 69 and 99 to 102.
The nucleotide change at position 11,433 of DEM 7C5. 17 resulted in a leucine to glutamine substitution at position 102. This change rendered the virus resistant to neutralization by MAbs 1H7, 1H9, 2B3, 5F8, 6A2, 7C5, and 8D4, but not to MAbs 3F4, 5E8, 7D4, and 10B4, which neutralize the virus to a titer of 400 to 12,800. These results suggest that the amino acid substitution at position 102 can affect both conformational and nonconfor- mational epitopes recognized by MAbs 1H7, 1H9, and recognized by MAb 1H9, which includes amino acids 69 and 99 to 102. 6A2; nonconformational epitopes recognized by MAbs 2B3, 5F8, and 8D4).
The nucleotide substitution at position 11,309 of DEM 5E8. 22 resulted in a lysine to glutamic acid change at The DEM 1H7. 13 had a nucleotide change at position 11,279 which resulted in an amino acid substitution at position 61 of the G L protein. DEM 5E8. 22 escapes neutralization by MAb 1H9, indicating that amino acid 61 is integral position 49 (aspartic acid to asparagine) and it was neutralized by all the MAbs raised to EM6D10 except MAb to the neutralization epitope recognized by MAb 1H9. The histidine at position 99 of EM 6D10 was changed 1H9. With the exception of DEMs 2B3. 20 and 2B3. 25 all the other DEMs were neutralized to variable titers to valine (DEM 2B3. 25), leucine (DEM 2B3. 20, 8D4. 18, and 10B4. 9), or proline (DEM 5F8.6), and these single (200-6400) by MAb 1H7. These data suggest that the epitope recognized by MAb 1H7 is independent but exsubstitutions were responsible for the altered neutralization phenotype of these viruses. With the sole exception erts some indirect conformational effect on the epitope of DEM 10B4. 9 these viruses were completely resistant the fact that these viruses are infectious and neutralized by MAb 1H7 and polyclonal equine antisera indicates to neutralization by MAb 10H4. DEM 10B4. 9, which had the same amino acid substitution as EM viruses 2B3. 20 that other neutralization sites must exist on the G L protein. and 8D4. 18, was neutralized to a lower titer (1600) by MAb 10H4 as compared to the control virus (X2. 4;
The control virus X2.4 (derived from parent virus EM6D10) had a single amino acid substitution at position 12,800). However, DEM 10B4.3 (another escape mutant to MAb 10B4) which lacked amino acids 100 and 101 113, which had no apparent effect on the neutralization phenotype of this virus. In a previous study, Glaser et al. escaped neutralization by MAb 10H4, indicating that the epitope recognized by MAb 10B4 is centered on the re-(1995) suggested that amino acids 99 and 100 are critical for virus neutralization and that amino acids 96 and 113 gion of amino acids 99 to 101 or that amino acid substitutions in this region may have a conformational effect might also contribute to the neutralization resistance of EM viruses. However, in our studies with a large panel on a distant site which may be deleted in DEM 10B4.3. Furthermore, DEM 7C5. 17, which had an amino acid of neutralization resistant viruses, field isolates and the ARVAC vaccine virus, we did not detect any changes in substitution at position 102 also escaped neutralization by MAb 10H4 which identifies an epitope at amino acids either amino acid 96 or 113 that clearly affected virus neutralization. Similarly, the glycine to serine substitution 102 and 103 (Balasuriya et al., 1995a) . Results of this study indicate that this epitope also can be affected by at position 113 of the control virus did not affect the neutralization phenotype of the virus. the amino acid at position 99, and these data further emphasize that amino acids 99 through 104 contain multiple interacting epitopes that are critical for neutralizaAmino acid changes in the G L protein of field strains tion of EAV. The MAbs 2B3, 5F8, 8D4, and 10B4 also and the vaccine strain of EAV and their possible failed to neutralize or immunoblot EAVUCD and EAVeffect on neutralization phenotype CVDLS (Table 3 ; representative example in Fig. 1 
, lane 8). The EM6D10 was derived from EAVUCD (Balasuriya
The amino acid substitutions in the G L protein of neutralization resistant variants of EAVUCD (EM 5G11, 6D10, et al., 1995a) and has a single amino acid substitution at position 99, which may have changed the major neu-7E5, 10H4, and DEM 6D10/10H4; Balasuriya et al., 1995a) and the DEMs in this study were compared to the amino tralization site of the G L protein and/or may have altered the conformation of this region. The MAbs raised against acid sequences of the G L protein of 19 field strains, four laboratory strains (EAVUtr, EAVATCC, EAVCVDLS, and EM 6D10 are produced to this ''altered'' neutralization site, which likely explains why they do not effectively EAVUCD) and the ARVAC vaccine virus. Amino acid substitutions in the G L protein of these viruses, as compared neutralize the original virus. Furthermore the four MAbs (2B3, 5F8, 8D4, and 10B4) which identified a common to EAVUtr, are shown in Fig. 2 . With the exception of VBS53 and PLD76, the field isolates had multiple substilinear epitope at position 99 selected neutralization variants with different amino acid substitutions at this positutions in the region of amino acids 67 through 90. Some of the amino acid substitutions in the field isolates and tion.
The ORF5 of DEM 3F4. 8 was 141 nucleotides (11,324-the vaccine virus were identical to those of individual neutralization resistant viruses [e.g., position 49 arginine 11,464; Table 4 ) shorter than that of the parent virus EM 6D10. Due to this 141 contiguous nucleotide deletion, in IL93TB; position 61 glutamic acid in KY93, MI93, IL93AB, IL93TB, CAN86, and CA95G; position 69 proline the G L protein of DEM 3F4. 8 was 47 amino acids (66-112; Figs. 2 and 3) shorter than that of EM 6D10 and in PLD76 and ARVAC vaccine virus (Figs. 2 and 3) ]. In addition, some of the field isolates had different amino EAVUCD (206 amino acids instead of 253 amino acids). Similarly, the sequence of ORF5 of DEM 10B4. 3 was acid substitutions at the same residue as the EM viruses (e.g., position 61 glutamine and aspartic acid in KY84 120 nucleotides (11, 437) shorter than that of the parent virus EM 6D10. Due to this 120 contiguous nucleoand NE88; position 104 glycine in ARVAC vaccine and PLD76, and asparagine in KY93, MI93, IL93AB, and tide deletion, the G L protein of DEM 10B4. 3 was 40 amino acids (62-101; Figs. 2 and 3) shorter than that of SWZ64). With the exception of PLD76 and KY63, and the ARVAC vaccine, the nonlaboratory strains of EAV (field the EM 6D10 and EAVUCD (213 amino acids). The amino acid deletion from residues 66-101 (36 amino acids) was strains) all had a second glycosylation site at position 81 of the G L protein. All eight cysteine residues (3 in the common to both deletion mutants. With the exception of MAb 1H7, which recognizes an epitope centered on V 1 region) were preserved in the G L protein of the field isolates, indicating that these are highly conserved. amino acid 49, both of these deleted viruses were not neutralized by any of the MAbs or polyclonal rabbit anti-
The neutralization phenotype of each EAV field isolate was determined by microneutralization assay using the EAV serum, indicating that they both lack a critical neutralization region of the G L protein. This data further con-17 MAbs to EAVUCD and EM6D10, as well as rabbit and equine polyclonal anti-EAV serum (Table 3 ). The SWZ64, firms the significance of amino acids 66 to 101 to the major neutralization site identified by the MAbs; however, PLD76, KY77, CAN86, MT89, MI93, IL93AB, CA95, and Chirnside et al. (1995) . **The synthetic peptide previously described by Balasuriya et al. (1995a) .
ARVAC vaccine viruses were not neutralized by any of and to generally low titers (32 to 1024) by MAbs raised to EAVUCD. The vaccine virus was neutralized to similar the MAbs raised to EM6D10 (Table 3) , whereas all the other field isolates were neutralized by the MAb 6A2 to titers as was PLD76 but they significantly differed in their neutralization by MAbs 5G11, 6D10, and 10H4. variable titers (64 to 512). PA76 was neutralized by all MAbs raised to EM6D10 to a titer of 64 to 128. MAb There were six amino acid substitutions in the V 1 region of the vaccine virus ( Fig. 2; positions 69 , 72, 100, 1H7 neutralized VBS53 to a titer of 128, and MAb 8D4 neutralized KY84 and ITA92 to a similar titer.
101, 104, and 106). Similar changes have been previously reported by Glaser et al. (1995) . Interestingly, the amino The MAbs to EAVUCD neutralized most of the field isolates of EAV to a titer of §64; however, some viruses acid substitution at positions 69 was similar to that present in some of the EM viruses. The vaccine virus also had significantly lower neutralization titers as compared to the EAVUCD prototype (Table 3) . For instance, the lacked the second glycosylation site at position 81. These findings indicate that the major neutralization reneutralization titer of PLD76 varied from 32 to 1024 as compared to 2048 to ú4096 for the prototype. Similarly, gion of the ARVAC vaccine virus is significantly different from that of other field isolates, which is reflected in its the AZ87 and vaccine viruses were generally neutralized to lower titer than the prototype. The data indicate that generally weak neutralization by the MAbs in our panel (Table 3) . Despite this variation, the ARVAC vaccine has there are significant antigenic differences among these viruses, with PA76 and PLD76 representing opposite exsuccessfully protected horses against clinical EVA (Timoney and McCollum, 1993). It is also appreciated that the tremes. PA76 was neutralized by all the 17 MAbs to a titer of §64 (highest titer ú4096), whereas PLD76 was epitopes recognized by murine MAbs may differ from those recognized by the horse. not neutralized by any of the MAbs raised to EM6D10 et al., 1991) for consistency. Significant amino acid changes are indicated by superscripts.
a As compared to the ORF5 sequence of EAVUCD parent virus (Balasuriya et al., 1995a) . b Uncharged polar amino acid to a basic amino acid. c Acidic amino acid to a uncharged polar amino acid. d Uncharged polar amino acid to a nonpolar amino acid. e As compared to the ORF5 sequence of EM 6D10 virus (Balasuriya et al., 1995a) . f Basic amino acid to a nonpolar amino acid. g Basic amino acid to a acidic amino acid. h Nonpolar amino acid to uncharged polar amino acid.
The neutralization of viruses isolated from the same the semen of a persistently infected stallion in California, indicated that this virus is antigenically distinct from geographic area sometimes varied, thus North American and European isolates were neutralized by individual some of the other field isolates of EAV. For instance the CAN86 virus, which was genetically related to CA95G MAbs to different titers. Similarly, some of the isolates made in the same year (e.g., 1993 isolates) varied from (Balasuriya et al., 1997b) , had a different neutralization phenotype but had only two amino acid (positions 73 and each other. The IL93TB and IL93AB viruses, for example, had different amino acid substitutions ( Fig. 2 ; position 82) differences in the V 1 region. 104 in IL93AB and position 49 in IL93TB) and also had distinct neutralization phenotypes (Table 3 ). The viruses DISCUSSION also were neutralized by the polyclonal equine anti-EAV sera to variable titers (32 to 512). The phenotypic charac-
The objective of this study was to further characterize the neutralization determinants of EAV using neutralizing terization of the CA95G virus, which was isolated from MAbs, neutralization-resistant EM viruses, and field et al. (1994) demonstrated that a neutralizing MAb bound the G L protein after much of the carboxy terminal portion strains of EAV from North America and Europe. All neutralizing MAbs in our panel bind linear or conformational (amino acids 116-211) was deleted, and we established that mice inoculated with a synthetic peptide that inneutralization determinants on the G L envelope glycoprotein. Sequence analysis of the DEM viruses localized cluded amino acids 93-112 of the G L protein developed neutralizing antibodies (Balasuriya et al., 1995a) . The Nall mutations and deletions responsible for their altered phenotype to a span of 186 nucleotides (11, 464) terminal ectodomain of the G L protein of EAV clearly contains major neutralizing determinants recognized by imin ORF5, and 64 amino acids (49 to 112) in the G L protein.
Substitutions of single amino acids at residues 49, 61, 69, mune sera from horses, rabbits, and mice, and most but not all of these determinants are located in the V 1 region. 99, and 102 of the G L protein clearly confer neutralization resistance to individual EM viruses, which is consistent
The panel of neutralizing MAbs identified significant antigenic variation among field isolates of EAV from North with results of a previous study in which we identified three interactive neutralization epitopes that included America (e.g., PA76, KY63, IL93AB, and IL93TB) and Europe (e.g., AUT68, PLD76, ITA92, and SWZ64). The neutralization amino acids 99-104 of the G L protein (Balasuriya et al., 1995a) . In another study, Glaser et al. (1995) also conphenotype of AZ87 is significantly different from that of all other isolates of EAV from North America and Europe, cluded that amino acids 99 and 100 of the G L protein constituted a major neutralization site of EAV. Data obalthough it is ancestrally related to the European viruses and was introduced into the United States by a persistently tained with the EM viruses indicate that amino acids 99-104 of the G L protein constitute a critical neutralization infected stallions imported from eastern Europe (Balasuriya et al., 1995b) . The data also indicate that there is antigenic site of EAV, and that other regions of the G L protein (e.g., amino acids 49, 61, and 69) likely exert a conformational variation among virus isolates derived from the same geographic area, as well as among isolates from the same influence on this site. With the notable exception of amino acid 49 [located in the C 1 region (amino acids 19-year or even the same outbreak of EVA. Some amino acid substitutions in the EM viruses also were present in field 60)], all other amino acid substitutions critical to neutralization resistance were localized to the V 1 variable region isolates (Figs. 2 and 3) , which is consistent with the variable neutralization of field strains of EAV by individual MAbs. of the G L protein.
The G L protein may function as both a receptor binding With the sole exception of IL93TB, most of the critical amino acid substitutions in the G L protein of field isolates were and membrane fusion protein (de Vries, 1994; de Vries et al., 1992) . The two deletion mutants (DEM 3F4. 8 and clustered in the V 1 region (Fig. 2 ) and the incidence of critical amino acid substitutions (e.g., at positions 61, 69, 10B4. 3 that, respectively, lack amino acids 66-112 and 62-101) retained their ability to infect cells and to pro-99, and 104) in field isolates would appear to have markedly increased since 1984. The major difference between the duce infectious progeny virus, which indicates that another receptor binding region of EAV may be located EM viruses (with the exception of the two deletion mutants) and field isolates is that none of the amino acid substitudistant to amino acids 62-112 of the N-terminal hydrophilic ectodomain of the G L protein, possibly between tions in the EM viruses occur between amino acids 71 and 90, whereas a large number of amino acids substitutions amino acids 19 and 61. With the notable exception of MAb 1H7 (which is specific for amino acid 49), the two are present in this region of the G L protein of the field isolates. The altered neutralization phenotype of the field deletion mutants were not neutralized by any of the MAbs or by the polyclonal rabbit antisera, indicating that the isolates of EAV strongly suggests that amino acids 71-90 either directly or indirectly influence other neutralization deleted portion of the G L protein includes the neutralization determinants recognized by rabbit antisera and all sites, which is consistent with data obtained with an immunogenic peptide (Chirnside et al., 1995) . Comparative analybut one of the neutralizing MAbs. The deleted EM viruses were neutralized by equine anti-EAV serum, although the sis of data obtained from the various field isolates and EM variants of EAV indicates that there are at least four potentiters were low with some sera (Table 2) , thus immune horse sera must recognize additional neutralizing epitial neutralization sites on the G L protein of EAV (Fig. 3) , including amino acids 49 (site A), 61 (site B), 67-90 (site topes that are not included in the deleted region. We previously have shown, however, that equine antisera to C), and 99-106 (site D).
All the field isolates of EAV, except KY63 and PLD76, EAV competitively inhibits the binding of neutralizing MAbs specific for amino acids 99-104 of the G L protein had a second glycosylation site at position 81, whereas the extensively cell culture passaged laboratory strains of EAV (Balasuriya et al., 1993) , thus this region also contains neutralization determinants of EAV recognized [EAVUCD, EAVCVDLS, EAV-NVSL (Glaser et al., 1995) , and EAVUtr (den Boon et al., 1991) ] and the ARVAC vacby infected horses. Furthermore, Chirnside et al. (1995) reported that horses developed neutralizing antibodies cine virus (Wilson et al., 1962; McCollum et al., 1961 McCollum et al., , 1962 all lacked this site. Interestingly, the VBS53 and after they were inoculated with either a fusion protein that included amino acids 55-98 of the G L protein or a ATCC strains of EAV have the second glycosylation site, whereas the laboratory strains do not, despite the fact synthetic peptide of amino acids 75-97. Similarly, Deregt that all these viruses ultimately were derived from the moving the new virus to a new fitness peak. In this crossing it may be advantageous for the variant to take a original Bucyrus strain of EAV. The EAVUCD, EAVCVDLS, and KY63 viruses, all of which lack the second glycosylalonger route (consisting of more mutations) if that enables it to avoid a particularly deleterious mutation. The tion site, had consistently high neutralization titers with the panel of MAbs raised against EAVUCD, as compared appearance of multiple amino acids substitutions in the V 1 region of the field strains of EAV, particularly in the to the PLD 76 and vaccine viruses, which also lack this site but were weakly neutralized by the same MAbs (speregion of amino acid 67-90 (site C) of different EAV strains, strongly suggests that these viruses are taking cifically with MAbs 7E5 and 9F2). The former three viruses (EAVUCD, EAVCVDLS, and KY63) also had the a longer route in order to generate stable variants with an altered phenotype. Interestingly, changes in this releast variation in neutralization sites A, B, and C as compared to EAVUtr, whereas, PLD 76 and ARVAC had amino gion were also consistently present in viruses isolated from the semen of persistently infected stallions (Balacid substitutions at critical positions (amino acids 69, 101, and 104) in the C and D neutralization sites (Figs. asuriya et al., 1997b; Glaser et al., 1995) . The effects of substitutions in the region of amino acids 67-90 on the 2 and 3). Furthermore, some viruses with the second glycosylation site were neutralized to high titer by the phenotypic variation of EAV, and the apparent increased incidence of clinical EVA since 1984 (Timoney and MAbs despite significant amino acid changes in sites B, C, and D (e.g., KY84, NE88, MI93). Divergent neutralizaMcCollum, 1987 , clearly warrants further investigation. tion phenotype, therefore, likely is dependent not only on the extent of glycosylation of the G L protein, but also In summary, comparative nucleotide and amino acid analyses of neutralization resistant variant viruses, as on the conformational influence of amino acids in other portions of the G L protein.
well as field and laboratory strains of EAV, indicate that there are mutational ''hot spots'' that are noncontiguous The high number of nonsynonymous amino acid substitutions in the V 1 region, particularly in the region of within the N-terminal ectodomain of the G L protein.
We have identified four neutralization sites on the G L protein amino acids 67-90 (site C), coupled with the presence of a second N-glycosylation site, may provide a selective ( et al., 1995a; Glaser et al., 1995) in the G L protein, and it may interact with the other three sites to form a large 3-individual strains of EAV could reflect an adaptive response of the virus to avoid host immune responses. dimensional (conformationally dependent) neutralization domain. Further studies will be required to determine Antibodies clearly can drive the selection of variant viruses; however, the extent of other selective forces, such whether immune selection of individual members of the virus quasispecies plays a critical role in evolution of as cell type and tissue tropism in influencing the fixation of amino acid substitutions within the G L protein during EAV, persistent infection of stallions, as well as the periodic emergence of virulent strains of this virus among the evolution of EAV is not clear.
Our studies have demonstrated that variation within endemically infected populations of horses. the V 1 region of the G L protein accompanies and likely facilitates adaptation and evolution of EAV (Balasuriya et ACKNOWLEDGMENT al., 1995b , 1997b Hedges et al., 1996) . Adaptive land-
